Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group plans to increase its stake in a pharmaceutical unit in Chengdu for a consideration of $10.8 million.

The company already holds a 93% stake in the target company, while the proposed acquisition will increase the same to 100%.

“The company already holds a 93% stake in the target company, while the proposed acquisition will increase the same to 100%.”

In another proposal by a Chinese company, Cachet Pharmaceutical, a majority stake of 51% is intended to be acquired in a pharmaceutical company based in Xi’an, China.

The deal value is proposed to be ¥18 million ($2.67 million).

US-based Antegrin Therapeutics and Cascadia Therapeutics have announced the completion of their merger.

The merged entity, named Indalo Therapeutics, aims to develop treatments for fibrotic diseases.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData